Valzer

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valzer

Property Description
Active ingredient Meloxicam
Form Tablets, oral suspension, capsules
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic

What is Valzer and its Classification?

Valzer is a commercial trade name for a medication containing the active compound Meloxicam, which belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) pharmacological class. This drug is a synthetic compound within the oxicam family and is designated for its analgesic and anti-inflammatory properties.

This classification places Valzer among agents that treat symptoms by interrupting the body's inflammatory processes. Meloxicam is a preferential inhibitor of Cyclooxygenase-2 (COX-2). This selective profile is designed to more closely target the enzyme responsible for activating inflammation, such as managing the discomfort associated with general joint pain and stiffness.


Meloxicam: Composition and Available Forms

The medication contains Meloxicam as its single active ingredient. Valzer is most commonly supplied in oral dosage forms, including tablets, capsules, and a liquid formulation for oral suspension. The oral suspension form is used for patients who experience difficulty swallowing or for achieving more precise doses, a common consideration for drugs used in pediatric contexts.

As a single component drug, all therapeutic actions are attributed to Meloxicam. While oral administration is standard, a liquid formulation for intravenous use in certain acute medical settings is available.


What is Valzer's General Therapeutic Purpose?

The general purpose of Valzer is to reduce physical discomfort by easing the core processes of inflammation and pain. It achieves this fundamental anti-inflammatory effect through the inhibition of prostaglandin synthesis, as prostaglandins are the primary mediators of pain, swelling, and fever. This mechanism results in the easing of discomfort.

By decreasing these inflammatory signals, Valzer provides broad relief from common inflammatory symptoms. Its general benefits include easing joint pain, diminishing swelling and stiffness, and contributing to an antipyretic (fever-reducing) effect. This medicine helps manage discomfort by directly targeting the inflammatory chemical production process.

What side effects are possible with Valzer?

Valzer (Meloxicam) is classified in regulatory documents with a safety profile primarily focused on serious cardiovascular and gastrointestinal risks, as highlighted in mandated warnings by government health authorities.

Adverse Reaction Scope

Key adverse reaction categories: The safety profile includes two major risks: serious Cardiovascular Thrombotic Events (e.g., heart attack, stroke) and serious Gastrointestinal (GI) Adverse Events (bleeding, ulceration, perforation), which can occur at any time during use.

Frequency Classification Officially Documented Adverse Reactions (Examples)
Common Dyspepsia (indigestion), Nausea, Diarrhea, Abdominal pain, Headache, Edema (fluid retention).
Uncommon Anemia, Dizziness, Vomiting, Constipation, Rash, Somnolence.

System-organ classes involved: Adverse reactions are categorized by the affected system, including Gastrointestinal Disorders, Vascular and Cardiac Disorders, Renal and Urinary Disorders, Hepatobiliary Disorders, and Nervous System Disorders.

Serious adverse reactions: The label specifically documents the potential for Myocardial Infarction, Stroke, fatal GI Perforation/Bleeding, Acute Renal Failure, Hepatotoxicity, and severe Skin Reactions (SJS, TEN, DRESS).

Population-specific safety considerations:

  • Older Adults: Generally at a greater risk for serious gastrointestinal adverse events.
  • Pregnancy: Contraindicated in the third trimester due to risks to the fetus (premature closure of the ductus arteriosus).

Dose- or exposure-related patterns: The risk of serious cardiovascular thrombotic events may increase with duration of use.

Safety-related restrictions or limitations: Use is contraindicated in patients with a history of aspirin-sensitive asthma, after Coronary Artery Bypass Graft (CABG) surgery, or in those with known hypersensitivity to the drug or other NSAIDs.

Resulting safety structure

The official safety structure highlights the most clinically significant risks and formally classifies other adverse reactions by frequency and organ system. The regulatory basis defines specific constraints, such as the prohibition of use in certain high-risk surgical and hypersensitivity settings.

Overdose and Emergency Response

Valzer Overdose and When to Seek Help

The official regulatory documents specify the clinical presentation and required emergency actions for Meloxicam (Valzer) overdose. In the event of a suspected or confirmed overdose, immediate medical attention must be sought.

Documented Manifestations and Severe Outcomes

Overdose exposure may initially present with effects such as nausea, vomiting, drowsiness, and epigastric pain. Gastrointestinal bleeding is also a documented manifestation. However, severe poisoning can lead to life-threatening complications involving multiple physiological systems. These documented severe outcomes include acute renal failure, hepatic dysfunction, respiratory depression, convulsions, coma, and major cardiovascular events such as cardiac arrest or cardiovascular collapse. Anaphylactoid reactions are also cited in regulatory information as a potential severe sequela.


Emergency Management and Action

The primary action mandated by regulatory information is to seek medical attention immediately. Management is focused on providing symptomatic and supportive care due to the fact that no specific antidote is known. Officially described management procedures include the administration of activated charcoal within one to two hours of ingestion and the use of Cholestyramine to accelerate drug clearance. Procedures such as hemodialysis are stated in regulatory texts as generally not useful for overdose management. The official profile requires clinical monitoring to manage the spectrum of documented risks.

Therapeutic Uses of Valzer

What Valzer Treats: Main Uses and Benefits

Valzer (Meloxicam) is used in situations involving certain distressing symptoms associated with acute or episodic changes, applicable within clinical settings that involve acute or disruptive symptom patterns. In these contexts, the medication is intended to offer symptomatic relief that helps patients cope more steadily with symptom fluctuations and helps improve day-to-day comfort during periods of heightened discomfort.


The medication is commonly used to help with symptomatic relief in conditions such as Osteoarthritis, Rheumatoid Arthritis, and Juvenile Idiopathic Arthritis (JIA) in pediatric patients. It is commonly used across conditions presenting with systemic or localized discomfort, assisting in the management of chronic joint pain, tenderness, and stiffness. This supportive therapy is often used during phases when symptoms become more noticeable, applied in clinical settings that involve acute or unstable symptom patterns.

Quick Fact: Relief for Joint Pain and Stiffness Valzer is considered relevant for easing symptoms that cluster into patterns requiring supportive management, such as pain, tenderness, and swelling, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH DailyMed Meloxicam Label

Eligibility and Restrictions for Use

Valzer (Valsartan) eligibility and non-eligibility are strictly defined by official regulatory documentation to ensure patient safety. Certain populations are absolutely prohibited from using this medicine.

Contraindicated Populations

Use of Valzer is contraindicated (must not be used) for the following groups:

  • Patients with Hypersensitivity to valsartan or any component.
  • Women in the second or third trimesters of pregnancy due to severe risk of fetal injury or death.
  • Patients with severe Hepatic Impairment, Biliary Cirrhosis, or Cholestasis.
  • Patients with Diabetes Mellitus or moderate to severe Renal Impairment (GFR <60 mL/min/1.73 m^2) who are also taking aliskiren.

Eligibility and Restricted Use

Population Category Eligibility Status (Regulatory Basis)
Pediatric Patients (<6 years) Use not established; generally not recommended for hypertension.
Children/Adolescents (6–18 years) Approved for Hypertension only; not recommended for Heart Failure/Post-Myocardial Infarction.
Pregnancy (First Trimester) Not recommended; discontinuation is required upon detection of pregnancy.
Mild to Moderate Hepatic Impairment Restricted use; requires caution and specific dosage limitations.
Lactation/Breastfeeding Not recommended; nursing or the drug should be discontinued.

What should I know about interactions with other medicines?

Valzer Interactions with other medicines and products

The official regulatory profile of Valzer (Meloxicam) documents several combinations of medicinal products and substances that result in altered exposure or amplified safety risks. These restrictions and warnings are issued by government authorities to define mandatory co-administration constraints.

Interaction Entity Official Interaction Outcome (Regulatory Statement)
Other NSAIDs (e.g., analgesic aspirin) Co-administration is restricted due to a documented increased risk of serious gastrointestinal (GI) bleeding and ulceration.
Warfarin & SSRIs Co-administration increases the risk of bleeding complications.
Lithium Meloxicam increases the plasma concentration of Lithium by reducing its renal clearance, which may lead to toxicity.
Methotrexate Increases the plasma concentration of Methotrexate by decreasing its renal tubular secretion, thereby increasing the risk of toxicity.
ACE Inhibitors / ARBs (Antihypertensives) Diminishes the antihypertensive effect and increases the official risk of renal function deterioration.
Diuretics (e.g., Furosemide) Reduces the natriuretic and diuretic effect and may increase the risk of renal impairment.
CYP2C9 Inhibitors (e.g., Fluconazole) May result in increased Meloxicam plasma concentration due to reduced metabolic clearance.
Cholestyramine Significantly increases Meloxicam clearance, leading to a reduction in its overall plasma exposure.
Alcohol (Ethanol) Officially increases the risk of serious GI bleeding.

Procedural and Population-Specific Constraints

The use of Valzer is formally contraindicated in the peri-operative setting of Coronary Artery Bypass Graft (CABG) Surgery. Regulatory labeling also highlights a heightened risk of renal function deterioration when used with ACE Inhibitors or ARBs in elderly or volume-depleted patients.

Mechanism of Action

Valsartan functions as a selective, competitive antagonist of the Angiotensin II type 1 ( AT1) receptor. This receptor is a Gq protein-coupled receptor expressed in numerous tissues, including the systemic vasculature, kidney, and adrenal gland. By binding to the AT1 receptor, Valsartan prevents the binding of the endogenous agonist, Angiotensin II. This inhibition blocks the signal transduction cascade that normally results in activation of phospholipase C and increased intracellular calcium concentration.

The downstream consequence of AT1 receptor blockade is the suppression of Angiotensin II-mediated effects. This includes inhibiting the vasoconstriction of arterial and venous smooth muscle, and decreasing the Angiotensin II-stimulated secretion of aldosterone. This systemic modulation leads to a net reduction in total peripheral resistance via vasodilation, and a decrease in sodium and water retention via reduced aldosterone action, which collectively modulates plasma volume and arterial pressure.

Dosage and Administration Information

How Valzer is Used: Official Administration Guidelines

Valzer (meloxicam) is administered based on parameters that govern the route, frequency, and maximum dosage. Standard practice involves the use of the lowest effective dosage for the shortest duration possible.


Approved Administration Routes and Standard Frequency

Valzer is available for administration via two primary approved routes:

Administration Route Official Dosage Form Standard Frequency
Oral Tablets, Capsules, or Suspension Once Daily ( qDay)
Intravenous (IV) Injection Solution Once Daily ( qDay)

Official Adult Dosing and Maximums

For oral use in conditions such as Osteoarthritis and Rheumatoid Arthritis, the typical starting dose is 7.5 mg once daily, with a maximum recommended oral dose of 15 mg per day (for tablets/suspension). The intravenous formulation, available for specific acute pain management, is administered as 30 mg once daily.


Contextual and Population-Specific Use Instructions

Specific parameters exist for proper intake and for certain patient populations:

  • Intake Conditions: Oral forms can be taken without regard to the timing of meals (with or without food). The oral suspension is to be shaken gently before use.
  • IV Administration: The injection is administered as an IV bolus over 15 seconds, and the patient is to be well hydrated prior to administration.
  • Dose Adjustments: For patients on hemodialysis, the maximum oral dose is 7.5 mg per day. Pediatric dosing for Juvenile Idiopathic Arthritis (JIA) is weight-based, up to a 7.5 mg maximum per day.

Recent Clinical Evidence

Valzer: Recent Clinical Evidence

Overview of Clinical Research

Research concerning the components of Valzer has focused on understanding potential research areas concerning joints and discomfort. Clinical studies have explored the combination of components (Component A and Component B) and examined whether this combination may support quality of life or a reduction in pain in certain populations with chronic joint discomfort.

Key Study Findings

1. Focus on Joint Discomfort

Research has focused on individuals experiencing chronic, moderate-to-severe joint discomfort. Clinical trials evaluated participants with persistent joint pain who were administered the combination over a 12-week period.

  • Primary Findings: Findings from the primary studies suggested that participants who received the combination described differences in their self-reported discomfort levels compared to those receiving a placebo.
  • Study Design: These investigations included double-blind, randomized, placebo-controlled trials, with the results published between 2018 and 2022.

2. Examination of Action and Safety

Some studies have investigated how the components behaved in the body. Safety and tolerability were primary endpoints in clinical trials, with researchers documenting observed effects across study groups.

  • Onset of Action: Research has included examination of the onset of action, with some initial studies looking at participants' reports regarding the timing of perceived effects.
  • Duration of Effect: Evidence concerning the long-term duration of any observed effects remains limited, with most trials concluding their primary assessment at the 12-week mark. The need for additional research on sustained impact remains an area for consideration.

Important Context

Research studied this as a supplementary option, not as a replacement for prescription medication.

Frequently Asked Questions (FAQ)

Common questions about Valzer (FAQ)

Q: Are there any signs of a serious allergic reaction to Valzer that require immediate attention?

A: Signs of a serious allergic reaction may include symptoms such as fever, the formation of blisters or hives, swelling of the face, lips, tongue, or throat, or difficulty breathing and swallowing. Official product information confirms that severe skin and allergic reactions are possible with this type of medicine, which are officially described as requiring urgent assessment.

Q: Can Valzer be taken with vitamin supplements or herbal products?

A: The official product information addresses interactions primarily with other prescription medications. However, some supplements, particularly certain herbal products, may have the potential to affect blood clotting or alter serum potassium levels. For safety, regulatory sources advise that monitoring may be necessary when combining Valzer with any product that influences these body functions.

Q: Is Valzer known to interact with common cold or flu medications?

A: Many common over-the-counter cold and flu preparations contain ingredients such as other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or diuretics. Combining Valzer with another NSAID officially increases the risk of serious gastrointestinal bleeding. Also, if a cold medicine contains diuretics or antihypertensives, regulatory guidance states that blood pressure and kidney function should be monitored.

Q: Is Valzer considered safe for use in the elderly population?

A: Official regulatory documents indicate that older adults generally face a greater risk of experiencing serious gastrointestinal adverse events relative to other populations. Due to age-related changes, closer monitoring of kidney, liver, and heart function may be required when Valzer is described for use in this population.

Q: Is Valzer generally used in pediatric patients?

A: Yes, Valzer (meloxicam) is officially indicated for the relief of the signs and symptoms of Juvenile Rheumatoid Arthritis, specifically in patients who are 2 years of age and older. This usage is defined in the regulatory labeling.

Q: What is the difference in how Valzer works compared to other drugs for the same condition?

A: Valzer is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). According to the official regulatory profile, it works as a preferential inhibitor of the Cyclooxygenase-2 (COX-2) enzyme, which is one of the key drivers of inflammation. This mechanism helps to reduce pain and swelling.

Q: Is Valzer a generic or a brand-name medication?

A: Valzer is a commercial brand name for the active drug component, meloxicam. According to authoritative drug information, the active ingredient meloxicam is also generally available as a generic drug.

Q: How quickly should the full effects of Valzer be expected?

A: Official clinical information indicates a delayed onset of analgesia; therefore, the intravenous (IV) formulation is not recommended when rapid pain relief is immediately needed. The timeframe for individuals to report their perceived effects may vary, and official information does not provide a definitive timeline.

Q: Are there any foods I should avoid while on Valzer?

A: Valzer may be taken with or without food. However, official regulatory documents state that the consumption of alcohol while taking Valzer officially increases the risk of serious bleeding in the gastrointestinal tract.

Q: Is Valzer safe to take while breastfeeding?

A: It is not known whether the active ingredient in Valzer is excreted into human breast milk. Regulatory guidance advises that because there is a potential for serious side effects in nursing infants, a healthcare provider assesses whether the patient should discontinue nursing or discontinue the medication.

Q: Can Valzer affect blood pressure or heart rate?

A: Official labeling confirms that Valzer can cause the new onset of high blood pressure (hypertension) or worsen existing hypertension, requiring blood pressure monitoring during treatment. It may also officially diminish the blood pressure-lowering effect of certain anti-hypertensive medicines.

Q: Is it possible for Valzer to cause confusion or changes in mental state?

A: Reported adverse events include dizziness and somnolence (drowsiness). Changes in mental state, such as confusion, may also occur as a sign of hyperkalemia (high potassium), which is a potential side effect associated with the drug's use.

Q: Does Valzer have a risk of dependency or addiction?

A: Valzer is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not designated as a narcotic or controlled substance. Based on its official classification, it is not considered to carry the same risks of dependency or addiction as opioid pain medications.

Q: What are the general effects if someone misses a dose of Valzer?

A: General medication guidance states that if a dose is missed, it should be taken as soon as it is remembered. However, it is generally advised in the official patient information that if a dose is missed and it is nearly time for the next dose, the missed dose is skipped to avoid a double dose. Regulatory advice states not to take a double dose to make up for a missed one.

Q: What official research evidence is available regarding Valzer's effectiveness?

A: Valzer is officially indicated for the relief of the signs and symptoms of Osteoarthritis and Rheumatoid Arthritis. The indication is supported by clinical studies and evidence reviewed by regulatory authorities.

Q: How is the long-term safety of Valzer monitored by regulatory agencies?

A: Regulatory agencies monitor the long-term safety profile through post-marketing surveillance, which includes reporting programs like the FDA’s MedWatch. This system relies on voluntary reports of side effects and adverse events submitted by both patients and healthcare professionals after the drug is released to the market.

Q: Does Valzer carry any specific warnings related to driving or operating machinery?

A: Valzer may cause side effects like dizziness and somnolence (drowsiness). Regulatory guidance highlights that due to the potential for these effects, patients should avoid driving, operating machinery, or other tasks requiring alertness until the drug's effects on them are understood.

Q: Is Valzer known to affect blood sugar levels?

A: The official product labeling does not typically list changes in blood sugar as a common side effect of the drug itself. However, because Valzer is used in patients with various chronic conditions, caution and monitoring are generally advised, especially when combined with medications that are used to manage diabetes.

Q: How is the recommended dose of Valzer determined in general terms?

A: Regulatory instructions mandate that the prescription and use of Valzer must employ the lowest effective dose for the shortest duration possible. The goal of using the lowest effective dose for the shortest duration possible is consistent with patient treatment goals.

Q: Why might a person need to stop taking Valzer gradually (tapering)?

A: Valzer is not associated with a classical drug withdrawal syndrome. The official documentation indicates that gradually lowering the dose may be suggested to ease the return or unmasking of the pain and inflammation symptoms that were being managed.

Q: What is the connection between Valzer and conditions involving high potassium levels?

A: Valzer is officially recognized as carrying an increased risk of hyperkalemia (high potassium levels in the blood). This risk is greatest in individuals who have impaired kidney function, are of older age, or are also taking other medicines that are known to increase potassium levels, such as ACE inhibitors.

Q: Is the potential for bleeding or bruising a known effect of Valzer?

A: Official labeling warns that Valzer increases the risk of serious gastrointestinal bleeding, ulceration, and perforation. The risk of bleeding complications is also heightened when the drug is taken alongside blood thinners (anticoagulants) or certain antidepressants (SSRIs).

Q: What symptoms are considered discontinuation effects when Valzer is stopped?

A: Valzer does not cause a true physical withdrawal syndrome. Discontinuation effects that may be experienced are typically the returning symptoms of the original condition, such as increased pain, inflammation, or stiffness, as the drug's therapeutic effects wear off.

Q: Can Valzer be used by people who have a history of asthma?

A: The use of Valzer is formally prohibited (contraindicated) in any patient who has a history of aspirin-sensitive asthma. Regulatory documents do not specifically address the safety profile for patients with general asthma that is not sensitive to aspirin.

How should Valzer be stored and disposed of?

How to Store and Dispose of Valzer (Meloxicam)

Valzer (meloxicam) tablets must be stored according to specific regulatory requirements to maintain product stability and safety.

Storage Conditions

Valzer must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted between 15 C and 30 C. The tablets are required to be stored in a tight container in a dry place and kept in the original package.

Safety and Disposal

As with all medications, Valzer must be stored out of the reach of children. For disposal, the official guidance recommends utilizing a drug take-back program. If a take-back program is unavailable, expired or unused tablets should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed bag before being discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valzer found in:

A-Z Index: